CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES

被引：0

作者：

de Botton, S. ^{[1
]}

Pollyea, D. A. ^{[2
]}

Stein, E. M. ^{[3
]}

DiNardo, C. ^{[4
]}

Fathi, A. T. ^{[5
]}

Roboz, G. J. ^{[6
]}

Collins, R. ^{[7
]}

Swords, R. T. ^{[8
]}

Flinn, I. ^{[9
]}

Altman, J. K. ^{[10
]}

Tallman, M. S. ^{[3
]}

Kantarjian, H. ^{[4
]}

Colby, K. ^{[11
]}

Fan, B. ^{[11
]}

Goldwasser, M. ^{[11
]}

Prahl, M. ^{[11
]}

Agresta, S. ^{[11
]}

Stone, R. M. ^{[12
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Colorado, Ctr Canc, Aurora, CO USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[8] Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[11] Agios Pharmaceut, Cambridge, MA 02139 USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P563

引用

页码：214 / 215

页数：2

共 50 条

[41] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
Harding, J.
Ikeda, M.
Goyal, L.
Rodon, J.
Bai, L.
Oh, D.
Park, J.
Chen, L.
Ueno, M.
Liao, C.
Kondo, S.
Cosman, R.
Yokota, T.
Shroff, R.
Satoh, T.
Palmieri, L.
Hollebecque, A.
Adeva, J.
Bender, M.
Liu, H.
Macarulla, T.
ANNALS OF ONCOLOGY, 2023, 34 : S161 - S161
[42] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
Natsume, Atsushi
Wakabayashi, Toshihiko
Miyakita, Yasuji
Narita, Yoshitaka
Mineharu, Yohei
Arakawa, Yoshiki
Yamasaki, Fumiyuki
Sugiyama, Kazuhiko
Hata, Nobuhiro
Muragaki, Yoshihiro
Nishikawa, Ryo
Shinojima, Naoki
Kumabe, Toshihiro
Saito, Ryuta
Ito, Kazumi
Tachibana, Masaya
Kakurai, Yasuyuki
Nishijima, Soichiro
Tsubouchi, Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Stein, Eytan M.
Altman, Jessica K.
Collins, Robert
DeAngelo, Daniel J.
Fathi, Amir T.
Flinn, Ian
Frankel, Arthur
Levine, Ross L.
Medeiros, Bruno C.
Patel, Manish
Pollyea, Daniel A.
Roboz, Gail J.
Stone, Richard M.
Swords, Ronan T.
Tallman, Martin S.
Agresta, Sam
Fan, Bin
Yang, Hua
Yen, Katharine
de Botton, Stephane
BLOOD, 2014, 124 (21)
[44] Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
Tap, William D.
Cote, Gregory Michael
Burris, Howard A.
Gore, Lia
Beeram, Muralidhar
Conley, Anthony Paul
Gianolio, Diego A.
Qu, Zhe
Gliser, Camelia
Pandya, Shuchi Sumant
Trent, Jonathan C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Roboz, Gail J.
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha L.
Donnellan, William B.
Erba, Harry P.
Mannis, Gabriel N.
Pollyea, Daniel A.
Stein, Anthony S.
Uy, Geoffrey L.
Watts, Justin M.
Fathi, Amir T.
Kantarjian, Hagop M.
Tallman, Martin S.
Choe, Sung
Dai, David
Fan, Bin
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Liu, Hua
Agresta, Samuel V.
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
BLOOD, 2018, 132
[46] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
Pollyea, Daniel Aaron
Dinardo, Courtney Denton
de Botton, Stephane
Stein, Eytan
Roboz, Gail J.
Mims, Alice S.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, William Bruce
Pigneux, Arnaud
Fathi, Amir Tahmasb
Liu, Hua
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Konteatis, Zenon
Artin, Erin
Nicolay, Brandon
Straley, Kimberly
Padyana, Anil K.
Jin, Lei
Chen, Yue
Narayaraswamy, Rohini
Tong, Shuilong
Wang, Feng
Zhou, Ding
Cui, Dawei
Cai, Zhenwei
Luo, Zhiyong
Fang, Cheng
Tang, Huachun
Lv, Xiaobing
Nagaraja, Raj
Yang, Hua
Su, Shin-San M.
Sui, Zhihua
Dang, Lenny
Yen, Katharine
Popovici-Muller, Janeta
Codega, Paolo
Campos, Carl
Mellinghoff, Ingo K.
Biller, Scott A.
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (02): : 101 - 107
[48] Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly- Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
DiNardo, Courtney D.
Roboz, Gail J.
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha L.
Donnellan, Will
Erba, Harry P.
Mannis, Gabriel N.
Pollyea, Daniel A.
Stein, Anthony S.
Uy, Geoffrey L.
Watts, Justin M.
Fathi, Amir T.
Kantarjian, Hagop M.
Tallman, Martin S.
Choe, Sung
Dai, David
Fan, Bin
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Liu, Hua
Agresta, Samuel V.
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S220
[49] Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
Chaturvedi, Anuhar
Gupta, Charu
Gabdoulline, Razif
Borchert, Nora M.
Goparaju, Ramya
Kaulfuss, Stefan
Goerlich, Kerstin
Schottmann, Renate
Othman, Basem
Welzenbach, Julia
Panknin, Olaf
Wagner, Markus
Geffers, Robert
Ganser, Arnold
Thol, Felicitas
Haegebarth, Andrea
Jeffers, Michael
Heuser, Michael
HAEMATOLOGICA, 2021, 106 (02) : 565 - 573
[50] Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia
Chaturvedi, Anuhar
Gupta, Charu
Goparaju, Ramya
Gabdoulline, Razif
Kaulfuss, Stefan
Gorlich, Kerstin
Schottmann, Renate
Panknin, Olaf
Wagner, Markus
Geffers, Robert
Ganser, Arnold
Thol, Felicitas
Jeffers, Michael
Haegebarth, Andrea
Heuser, Michael
BLOOD, 2017, 130

← 1 2 3 4 5 →